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Abstract
The understanding of neuromyelitis optica spectrum disorder (NMOSD) has evolved substantially since its initial description over a century ago. The discovery in 2004 of a pathogenic autoantibody biomarker targeting aquaporin 4 IgG revolutionized diagnosis and therapeutic development. Although NMOSD resembles multiple sclerosis (MS), differences were identified and articulated in the late 1990s. New diagnostic criteria incorporating the biomarker as well as better understanding of the clinical and radiologic features of NMOSD now permit accurate diagnosis and differentiation from MS. Aquaporin 4 IgGeassociated NMOSD is now regarded as an immune astrocytopathy with lytic and nonlytic effects on astrocytes. A second autoantibody, myelin oligodendrocyte glycoprotein IgG, which targets myelin rather than astrocytes, leads to an NMOSD syndrome with clinical and radiologic features that overlap but are distinct from those of aquaporin 4 IgGeassociated NMOSD and MS. We review current understanding of the clinical aspects, pathophysiology, and treatment of NMOSD. T he definition of neuromyelitis optica (NMO) spectrum disorder (NMOSD) has evolved over the past 150 years since the initial description of a syndrome manifested by selective severe optic nerve and spinal cord inflammation 1, 2 ; the propensity and selectivity for optic nerve and spinal cord involvement has been a mystery. Although this condition resembled multiple sclerosis (MS), which is also characterized by acute self-limited attacks of optic neuritis and myelitis, differences between these conditions were articulated in the late 1990s, and subsequent diagnostic criteria permitted accurate clinical and radiologic distinction. 3 The discovery of a pathogenic autoantibody biomarker, AQP4-IgG, an immunoglobulin targeting aquaporin 4 (AQP4), 4, 5 revolutionized diagnosis and continues to inform therapeutic development. Because a specific diagnosis could be made in the presence of the biomarker, exclusive targeting of the optic nerve and spinal cord were no longer the exclusive basis for diagnosis. Nonopticospinal clinical syndromes within (and rarely outside) the central nervous system (CNS) were recognized as compatible with the disease and even as hallmarks, the most characteristic of these being inflammation of the area postrema, manifested as intractable vomiting or hiccups. 6 Two schools of thought emerged regarding diagnosis and classification. One held that AQP4-IgG defined a specific syndrome, making molecular diagnosis (AQP4-IgGeassociated disease) possible and, indeed, preferable to clinically based diagnosis (NMOSD). 7 The other held that the sensitivity and specificity of AQP4-IgG is not yet adequately established and that seronegative NMOSD cannot be adequately distinguished from seropositive NMOSD; accordingly, clinical criteria for NMOSD are still appropriate, AQP4-IgG being an important, but still supportive, diagnostic test. 8 Autoantibodies targeting myelin oligodendrocyte glycoprotein (MOG) are now increasingly recognized as defining an overlapping clinical syndrome that often satisfies the clinical diagnosis of NMOSD. [9] [10] [11] Aquaporin 4 IgGeassociated NMOSD is an immune astrocytopathy with lytic and nonlytic clinical consequences to astrocytes. 12, 13 Conversely, MOG IgGeassociated NMOSD appears to target myelin and not astrocytes and does not lead to elevation of markers of astrocyte injury in the context of attacks. 14 Emerging understanding of the pathogenic antibodies is driving contemporary treatment and clinical research on NMOSD and has spawned several clinical trials targeting B cells and complement-mediated activation by AQP4-IgG. We discuss current understanding of the clinical aspects, pathophysiology, and treatment of NMOSD.
DIAGNOSIS OF NMO/NMOSD
Historical Overview and Nosology Case reports describing opticospinal syndromes compatible with NMOSD date back to 1804. 15 Eugene Devic and his student, Francis Gault, synthesized their experience with a case and review of the available literature in a report proposing that the described cases represented a distinct clinical entity, neuromyélite optique aiguë. 16 Their limited experience defined "Devic disease" over most of the next century; the diagnosis was usually made in a patient with a monophasic syndrome of severe, near-simultaneous optic neuritis and myelitis. However, relapsing cases and cases in which pathologic examination revealed involvement of the cerebrum and brain stem led some to question whether NMO differed from MS. 17 In the late 20th century, the advent of magnetic resonance imaging (MRI) documented that NMO-associated transverse myelitis was accompanied by longitudinally extensive spinal cord lesions (contiguous lesion extending over >3 vertebral segments) ( Figure 1 ) and that brain MRI findings were usually normal. 3, 18 Cerebrospinal fluid (CSF) analysis also revealed findings distinct from MSdspecifically, the absence of oligoclonal bands and, in a minority of patients, a prominent, occasionally neutrophil-predominant pleocytosis during a relapse. 3, 18 Initial diagnostic criteria devised in 1999 required both transverse myelitis and optic neuritis but no other evidence of clinically manifest CNS disease. 3 The aforementioned MRI findings and prominent or neutrophilic CSF pleocytosis were supportive criteria in distinguishing NMO from MS.
The discovery of AQP4-IgG and demonstration of its specificity for NMO, reported in 2004, 4 supported NMO being distinct from MS. The presence of AQP4-IgG was incorporated into the diagnostic criteria for NMOSD in 2006. 19 Observational studies of AQP4-IgGeseropositive patients identified "NMO spectrum disorders," 20 which are clinical and MRI findings associated with AQP4-IgG seropositivity. These disorders include limited forms of NMO (single or recurrent longitudinally extensive transverse myelitis [LETM] events or recurrent isolated optic neuritis), Asian optic-spinal MS, 21 optic neuritis or LETM associated with systemic autoimmune diseases, 22 or distinctive "NMO-typical" MRI findings (see Current Diagnostic Criteria section). 23, 24 The evolving definitions of NMO/NMOSD indicate that the disease is severe, usually follows a relapsing course, and rarely converts to a secondary progressive phenotype. 25 
Current Diagnostic Criteria
In 2015, the International Panel for NMO Diagnosis (IPND) proposed revised consensus NMOSD clinical diagnostic criteria (Table 1) 8 FIGURE 1. Neuroimaging patterns associated with neuromyelitis optica spectrum disorder (NMOSD). A, Axial T1-weighted magnetic resonance image shows signal abnormality involving the optic chiasm after intravenous gadolinium administration (arrow). B, Sagittal magnetic resonance image shows a longitudinally extensive transverse myelitis lesion that extends into the brain stem on T2-weighted imaging (arrow). C, On T1-weighted sagittal imaging, the lesion has central hypointensity and regions of surrounding gadolinium enhancement (arrow). D, Sagittal fluid-attenuated inversion recovery image showing a characterstic periepenymal lesion involving the dorsal pons and medulla (arrow). Spinal cord lesions in NMOSD typically involve the central gray matter, as seen on T2-weighted axial cord imaging (E) (arrow) and may also reveal "bright spotty lesions" associated with the disease (F) (arrow). G, Axial fluidattenuated inversion recovery image showing periependymal brain involvement (arrows), H, Acute lesions may enhance on T1-weighted postegadolinium imaging (arrows). I, Lesions oriented along the anterior-posterior axis of the corpus callosum or involving the splenium are also characteristic of NMOSD (arrows).
to account for the expanding array of clinical and MRI findings associated with AQP4-IgG and because the ability to diagnose NMOSD and distinguish it from MS was often possible at initial presentation, especially in AQP4-IgGeseropositive patients. Increasing evidence that MS disease-modifying therapies, including interferon beta, natalizumab, fingolimod, and alemtuzumab, aggravate NMOSD has made early diagnosis essential. [26] [27] [28] [29] The IPND criteria incorporate both NMO and NMOSD as previously defined into a single entity and stratify patients on the basis of AQP4-IgG serostatus (eg, NMOSD with AQP4-IgG and NMOSD without AQP4-IgG). For patients with AQP4-IgG and no better alternative diagnosis, a single clinical event referable to 1 of 6 neuroanatomically defined CNS regions (optic nerve, spinal cord, area postrema, brain stem, diencephalon, or cerebrum) is sufficient for diagnosis. Novel features of the IPND criteria for NMOSD with AQP4-IgG include (1) a single clinical event is sufficient for diagnosis, (2) transverse myelitis attacks need not meet the LETM MRI criterion, 30 (3) "area postrema syndrome" of intractable nausea, vomiting, and/or hiccups (owing to a lesion in the dorsal medulla), which occurs at some point in up to 40% of patients, 31, 32 is recognized as a hallmark syndrome with the same diagnostic specificity as optic neuritis and myelitis, and (4) identification of "NMO-typical" MRI lesions of the diencephalon (hypothalamus and thalamus) or cerebrum, which are more specific than the clinical syndromes with which they are associated. 24 Cell-based AQP4-IgG assay with conformationally preserved target is strongly recommended because of its greater sensitivity (w75%) and specificity (95%-100%) than enzyme-linked immunosorbent assays. 33 Serum testing is sufficient, and CSF AQP4-IgG adds little, if any, sensitivity. 34 The IPND defined NMOSD without AQP4-IgG more stringently than seropositive disease because the differential diagnosis comprises other conditions including sarcoidosis, neoplasms, and a variety of paraneoplastic disorders. Diagnosis requires involvement of 2 or more of the 6 CNS regions, at least 1 of which must be from the 3 most common presentations: optic neuritis, transverse myelitis (LETM MRI lesion required), or area postrema syndrome (dorsal medulla MRI lesion required). Typically, 2 or more attacks are necessary to establish the diagnosis, but "classic" NMO (a single event of optic neuritis and LETM-associated myelitis) would qualify. Recurrent isolated episodes of optic neuritis or myelitis do not qualify in the absence of AQP4-IgG given the broad differential diagnosis of these syndromes. However, NMOSD cannot be excluded in this situation, and patients should be followed up for emergence of new indications of NMOSD or other competing diagnoses. The IPND identified clinical, MRI (Figure 1 ), or other characteristics favoring NMOSD that may be especially helpful in seronegative cases. For example, optic chiasm involvement, 35, 36 "longitudinally extensive" lesions of greater than half of the optic nerve length, predominant involvement of the posterior optic nerve, and bilateral optic neuritis favor NMOSD as a cause. The IPND described a number of clinical and neuroimaging "red flags" of potential alternative diagnoses and provided guidance for serologic retesting in AQP4-IgGeseronegative patients, especially at the time of a breakthrough attack when AQP4-IgG titer may increase. 26 The IPND also confirmed applicability of the 2015 criteria to pediatric cases but noted that a greater proportion of children present with cerebral syndromes and that LETMassociated myelitis is not as strongly associated with NMOSD in children as in adults. 37, 38 Finally, the IPND concluded that Asian optic-spinal MS is, in most cases, the same disorder as NMOSD.
Further advances in the nosology of NMOSD will depend in part on determination of whether other pathogenic autoantibodies are detected in the 30% of patients with NMOSD who are AQP4-IgG seronegative. Myelin oligodendrocyte glycoprotein IgGeseropositive patients comprise about 25% of those patients. The clinical features of MOG-IgGeassociated NMOSD overlap with those of AQP4-IgGeassociated NMOSD, but there appear to be group differences in demographic and clinical features including a lesser predilection for women, disproportionately greater optic nerve involvement, lesser tendency for relapse, and predilection for caudal spinal cord myelitis. 9 Although initially suggested to be a condition that is less severe and less likely to recur, this variant does lead to frequent relapses and substantial disability in some patients, with a disproportionate number experiencing impaired optic nerve function. [39] [40] [41] [42] Myelin oligodendrocyte glycoprotein IgG assays are not yet widely available.
EPIDEMIOLOGY OF NMO
A number of factors should be considered when evaluating epidemiological studies of NMOSD. Contemporary appreciation of NMOSD spectrum and its distinction from its common mimic, MS, occurred over the past 2 decades. The widely accepted biomarker for NMOSD, AQP4-IgG, was first reported in 2004. Before that, NMOSD was rarely diagnosed except in patients with bilateral optic neuritis and myelitis occurring in quick succession who did not experience relapse; this subgroup accounts for a small minority of cases now diagnosed with NMOSD. Different clinical labels, including Devic disease and Asian (Japanese) opticospinal MS, were applied in different countries to patients currently recognized as having NMOSD; some, but not all, patients with these diagnoses had NMOSD. International acceptance of nomenclature and contemporary definition has recently been achieved 8 but likely will continue to evolve. Finally, NMOSD is likely a heterogeneous condition, exemplified by 2 clinically overlapping syndromes, AQP4-associated and MOG-IgGeassociated NMOSD, which appear to differ in sex distribution and age at onset. 9 With these caveats, NMOSD is a worldwide disease affecting women and men ranging from 3 to 80 years of age. 43 Middleaged and elderly women are most commonly affected, the average age at onset being 40 years. Preadolescent children do not have a sex predilection, but after adolescence, women predominate and constitute 70% to 90% of affected individuals. 38 There is a predilection for nonwhites, 44 although individuals of all races and ethnicities are affected.
Contemporary studies utilizing the 2006 criteria of Wingerchuk et al, 19 which were widely accepted as the international standard until 2015, report prevalence rates ranging from 0.54 per 100,000 (Cuba) to 4.4 per 100,000 (Denmark) ( Table 2) . [44] [45] [46] [47] [48] [49] [50] [51] [52] Rates from Japan (0.9 per 100,000) were comparable (0.72 per 100,000) or lower (1.96 per 100,000) than those reported from the United Kingdom. 43 A seroprevalence study from Olmsted County, Minnesota, and Martinique that systematically tested all individuals with suspected inflammatory demyelinating disease for AQP4-IgG found the prevalence in Martinique to be 3-fold higher than previously reported (10 per 100,000) and 2.5-fold more common than in Olmsted County (3.9 per 100,000). 44 In both geographic regions, blacks were overrepresented compared with expected rates, and the prevalence in the black and white populations did not differ between the 2 geographic regions, suggesting that ethnicity is a key determinant of prevalence. Familial aggregation is occasionally observed 53 and will be discussed subsequently (see "Genetic Factors" section). Environmental factors have largely been unexplored, and no studies of NMOSD in migrants compared the populations from which they arose to address whether risk is mutable, although as noted, the prevalence of similarly defined NMOSD does not seem to vary considerably on the basis of geography. Myelin oligodendrocyte glycoprotein IgGeassociated NMOSD occurs more frequently in men and in younger individuals than AQP4-IgGeassociated NMOSD. 9 
PATHOGENESIS OF NMO
Most patients with NMOSD have AQP4-targeting, polyclonal IgG1 autoantibodies capable of modulating AQP4 from the cell surface in vitro and inducing complementmediated lysis of target cells in the presence of complement. 54 Passive transfer of AQP4-IgG from patients by direct intracerebral injection 55 or peripherally in rodents after blood-brain barrier disruption by experimental autoimmune encephalomyelitis or other means [56] [57] [58] yields lesions with pathologic features of NMOSD lesions. Aquaporin 4 knockout mice are completely protected. 55 These experiments, along with beneficial effects of plasma exchange 59 and suppression of ongoing attacks by complement inhibitors 60 and rituximab, 61, 62 suggest that NMOSD is an antibody-mediated aquaporinopathy. Myelin oligodendrocyte glycoprotein IgG is detected in approximately 25% of AQP4-IgGeseronegative individuals, can induce pathology in mice, 63 and may be an alternative mediator of AQP4-IgGeseronegative, autoantibody-mediated NMOSD. 9 Any theories of pathogenesis must explain the following key observations: (1) selectivity for the optic nerve and spinal cord, and, to a lesser but still notable degree, for the area postrema and other circumventricular organs of the brain; (2) evidence of perivascular inflammation accompanied by evidence of complement ; (4) rare association with cancers, which in some instances also express the target antigen established for NMO, AQP4 [65] [66] [67] [68] ; and (5) emerging pathologic evidence of a diffuse, nonlytic astrocytopathy in addition to a lytic astrocytopathy. 12, 69, 70 Recent research yields some answers about many of these phenomena and offers rationale to current and future treatment strategies for NMO (Table 3 and Figure 2 ). Recent advances are reviewed in the following sections, concentrating on AQP4-IgGeseropositive NMOSD.
Predisposing Factors and Associations
Genetic Factors. Neuromyelitis optica is generally a sporadic disease, although familial cases have been reported and constitute at least 3% of cases, a frequency higher than expected by chance given its rarity; current data regarding familial segregation is most consistent with non-Mendelian polygenic inheritance. 53 There is no, or perhaps a negative, association with HLA-DRB1*1501, the allele most strongly and consistently associated with MS, with which NMOSD was commonly confused. 53, 71 Furthermore, a single study evaluating 35 nonemajor histocompatibility complex MS susceptibility loci in 110 patients with NMOSD compared with 332 controls found no association of these alleles with NMOSD. 72 These data further support the current hypothesis that MS and NMOSD are distinct entities. Neuromyelitis optica spectrum disorder is associated with HLA-DRB1*03, an allele also associated with other autoimmune conditions including systemic lupus erythematosus (SLE). 71 In Brazil, NMOSD has stronger association with African and weaker association with European ancestry genes than MS, although European ancestry genes predominate in both conditions. 73 Two studies examining AQP4 polymorphisms have not convincingly confirmed any association with NMOSD, although a rare allelic variant seemed to segregate with susceptibility in one pedigree. 74, 75 Limited numbers of positive associations of candidate genes have yet to be confirmed.
Autoimmunity.
Neuromyelitis optica is commonly associated with other systemic autoimmune diseases. Multiple, often hightiter, autoantibodies associated with autoimmune disease are even more commonly detected in those without clinical illness. The most frequent coassociations are with thyroid autoimmunity, SLE, and Sjögren syndrome (SS). However, a general increase in autoantibodies, including AQP4-IgG in patients with systemic autoimmunity, does not explain the association with SLE and SS. Individuals with SLE and SS but without symptoms of myelitis and optic neuritis are consistently seronegative for AQP4-IgG. 22 Autoimmunity affecting the nervous system has also been reported, including myasthenia gravis 76 and more recently paraneoplastic and limbic encephalitis and N-methyl-D-aspartate receptor encephalitis. 77, 78 An important clinical correlate to consider is whether a given symptom or imaging abnormality is a direct result of NMOSD or related to comorbidity. The excess figure) , where it interacts with AQP4 proteins, encoded on chromosome 18, and is expressed on astrocyte endfeet that abut blood vessels and the pia mater and lead to complement activation by classic pathway of C1q binding. Aquaporin 4 supramolecular aggregates consisting of the M23 isoform decorated on their periphery by M1 isoform are particularly prone to C1q binding and complement activation when they interact with AQP4-IgG. Aquaporin 4 binding may lead to lytic damage due to complement activation or may lead to activation of astrocytes and an inflammatory milieu due to NF-kB signaling. Intervention strategies or drugs that are being considered or are in current use are shown in red font where they are thought to act in the pathophysiology of neuromyelitis optica spectrum disorder. APC ¼ antigen presenting cell; IL-6¼ interleukin 6; IL-6R ¼ interleukin 6 receptor; M1, M23 ¼ dominant isoforms of AQP4; mAb ¼ monoclonal antibody; EAAT2 ¼ excitatory amino acid transporter 2; MHC-1 ¼ major histocompatibility complex 1 protein; TcR ¼ T-cell receptor.
of autoimmune disease in patients with NMOSD remains unexplained, although a variety of autoimmune diseases may occur in individuals with allelic variants that affect immune tolerance. A recent report of a patient with coexisting Aicardi-Goutières syndrome and NMOSD suggests that conditions impairing immune function may lead to a milieu favoring development of NMOSD. 79 Paraneoplastic Disease. A small percentage of patients with NMOSD have coexisting cancers of a variety of types, 65, 67, 68 and in rare instances, AQP4 expression has been documented in the tumor associated with inflammatory changes. 65 These cancers may initiate the humoral autoimmune process leading to NMOSD, although the specificity of paraneoplastic AQP4 expression for NMOSD remains to be established.
Other. Limited studies have addressed other predisposing factors. One study found no clear association of smoking or markers of previous Epstein-Barr virus exposure in patients with NMOSD. 80 A retrospective study reported that patients with recurrent spinal cord inflammatory disease, 61% of whom were seropositive for AQP4-IgG, had lower vitamin D levels than those with monophasic disease.
Immunopathogenesis T Cells. Aquaporin 4 IgG is an IgG1 antibody.
IgG1 synthesis is dependent on T-cell help. Peripheral T cells exhibit antigen-specific reactivity to AQP4. Aquaporin 4 antigenic stimulation polarizes the immune system toward a helper T-cell subtype 17 repertoire. 81 The immunodominant peptide located at the N-terminus of AQP4 is 90% homologous with a 10eamino acid sequence of a Clostridium perfringens adenosine triphosphateebinding cassette transporter permease. 81 A recent study found an overabundance of C perfringens in the microbiome of patients with NMOSD compared with healthy controls, although other organisms were also overrepresented. 82 Other immunodominant peptides of AQP4 have been reported. Interleukin 6 (IL-6) is an important trophic factor for plasmablasts, and inhibition of IL-6 receptor by tocilizumab has shown promise as a treatment. 85 A recent publication summarizes current concepts on the role of B cells in NMOSD. 86 Cytokine Networks. Cytokine activation may provide insight into the nature of contributing immune cell subsets and other clues to pathogenesis; analysis of cytokine elevation in NMOSD has suggested involvement of helper T-cell subtype 17 pathway activation. Interleukin 6 has been consistently overexpressed in NMOSD and is associated with disease activity; as noted, it may promote B-cell survival among other pathogenic mechanisms. B-cell activating factor is also overexpressed in NMO.
Antigen Expression. Aquaporin 4 is expressed predominantly on astrocytes of the CNS, principally on the astrocyte foot process where it is molecularly linked to the dystrophin complex that directly abuts the endothelial cells and comprises the glia limitans at the pial surface. This localization explains, in large part, the "vasculocentric" nature of the pathology and the colocalization of AQP4-IgG binding with abluminal surface markers such as laminin rather than with factor VIII, an endothelial marker. 4 Aquaporin 4 is physically linked with excitatory amino acid transporter 2. Binding and complement activation result in markedly reduced immunoreactivity in NMOSD lesions, which may impair glutamate clearance. Aquaporin 4 is expressed as the tetramer of 2 dominant isoforms transcribed from the same gene, which differ by 22 amino acids at the N-terminus that are present in M1 but absent in M23. Aquaporin 4 tetramers are further assembled into supramolecular aggregates of large size identified by freeze-fracture electron microscopy. The molecular interactions between the isoforms that lead to supramolecular aggregation have been characterized. Binding of AQP4-IgG requires supramolecular aggregation. 87 Although the level of AQP4 expression was similar in a single case in nonlesional tissue compared with controls, the optic nerve and spinal cord differ greatly in levels of expression of both isoforms and the degree of supramolecular aggregation, providing a plausible explanation for selective targeting of optic nerves and spinal cord by AQP4-IgG. 88 Furthermore, low levels of expression and colocalization of complement-inhibitory proteins with AQP4 in the CNS may predispose the CNS to AQP4-IgGemediated pathology compared with non-CNS tissues.
89
Complement and Other Downstream Effectors. The principal effector mechanism for NMO attacks is complement-mediated inflammation and its downstream consequences including generation of chemoattractants and secondary neutrophils and eosinophil toxicity. 64 Complement inhibitors have shown promise in uncontrolled studies. 60 Neutrophil product and eosinophil inhibitors have also shown promise in vitro. 90, 91 However, nonlytic changes may also occur in certain parts of the brain, best demonstrated for the area postrema. 6 Extensive loss of immunoreactive AQP4 may occur without demyelination and may suggest lesion reversibility. Widespread reactive astrocytic changes of unclear clinical importance occur in the brain but could contribute to cognitive dysfunction in NMOSD as reported by some investigators. 92 TREATMENT OF NMOSD Because NMOSD attacks require aggressive treatment and appropriate preventive therapy, early accurate diagnosis is important. Although several randomized controlled trials of preventive therapies are in progress, current treatment decisions are based primarily on data from uncontrolled retrospective and prospective observational studies. At present, no compelling data indicate that treatment decisions differ in NMOSD on the basis of AQP4-IgG serologic status.
Immune-Directed Therapy Acute attacks are treated with intravenous corticosteroids (eg, methylprednisolone, 1000 mg daily for 5 consecutive days). A series of 5 to 7 plasma exchange procedures serves as rescue therapy for severe, corticosteroidunresponsive attacks. 93, 94 A recent retrospective study suggests that plasma exchange may be more efficacious as primary therapy for an acute attack than corticosteroids, but this theory requires further study. 95 Similarly, the effectiveness and role of intravenous immunoglobulin or cell-depleting therapies require more study.
Long-term relapse prevention therapy is recommended for all AQP4-IgGeseropositive patients and for AQP4-IgGeseronegative patients with established relapsing disease. 96 Multiple sclerosis disease-modifying therapies must be avoided; beta interferons, natalizumab, fingolimod, and alemtuzumab may aggravate NMOSD. [26] [27] [28] [29] Glatiramer acetate appears to be ineffective. 97 When diagnostic uncertainty exists between NMOSD and MS, especially in AQP4-IgGeseronegative patients, we recommend an NMOSD-suitable immunosuppressive strategy, which will be effective for both conditions. Contemporary treatment approaches (Table 4) all involve immunosuppression, but no regimen has been proved to be superior given the absence of completed randomized, placebo-controlled trials that either establish the magnitude of benefit for any single agent or provide head-to-head comparisons of 2 or more therapies. 98 The most commonly used treatments include the oral drugs azathioprine and mycophenolate mofetil (MMF) and the intravenous anti-CD20 monoclonal antibody rituximab. Retrospective and limited prospective cohort data suggest that these immunosuppressive therapies result in relapse-free rates of 25% to 66% during variable follow-up durations. 61, 62, [99] [100] [101] [102] [103] [104] In the absence of evidence from controlled trials and therapeutic biomarkers, the choice of initial therapy depends on availability, comorbidities, and disease course. Some retrospective case series suggest that azathioprine is less effective than the other 2 drugs, 105 although similar-quality evidence suggests that regardless of which initial therapy is selected, most patients can achieve remission with 1 of the first 2 drugs they try. 106 Azathioprine is inexpensive and widely available, but adherence rates are low and thiopurine methyltransferase deficiency is a relative contraindication. Full biological activity of azathioprine and MMF is delayed by 4 to 6 months after initiation, necessitating concomitant "bridge" 107 Rituximab has several advantages, including easily tracked adherence and rapid onset of action, as it results in B-cell depletion within 2 weeks of course completion. Other reportedly beneficial approaches include long-term oral low-dose corticosteroids, 108 oral methotrexate, 109 and intravenous mitoxantrone, 110 all of which are relatively accessible in developed nations.
Enhanced understanding of NMOSD pathophysiology has allowed identification of many other candidate immunotherapies. 111 In a prospective open-label trial, 14 patients received intravenous eculizumab, a monoclonal antibody that targets C5, the terminal component of complement. 60 At 12 months, 12 of the 14 patients remained relapse free, and 5 experienced relapse after eculizumab withdrawal. Eculizumab is 1 of 3 therapies currently being studied in NMOSD randomized controlled trials. 112 The other 2 are inebilizumab, an anti-CD19 monoclonal antibody also known as MEDI-551, and SA237, an antieIL-6 receptor monoclonal antibody. Inebilizumab is a B-cell depletion agent with a potential advantage over rituximab because of its ability to deplete plasmablasts. SA237 is similar to tocilizumab and is of interest because of the identified role of IL-6 in NMOSD pathogenesis. 113, 114 Once NMOSD diagnosis is confirmed and preventive treatment initiated, disease monitoring consists mainly of detecting breakthrough attacks, laboratory surveillance for safety, and adherence monitoring. The goal of preventive immunotherapy is absence of attacks; because NMOSD rarely converts to a secondary progressive course, prolonged relapse-free remissions should be associated with neurologic stability or improvement. There are no validated therapeutic biomarkers for NMOSD, but a recent report that fragment c gamma receptor 3A allelic variants may predict lack of rituximab response shows potential for individualized therapy. 115 Aquaporin 4 IgG titers may increase in the periattack period but may not predict attacks. Similarly, although serum Highthroughput screening has identified small molecules that competitively inhibit pathogenic AQP4-IgG binding. 117 Finally, alteration of circulating AQP4-IgG through cleavage or deglycosylation can render it nonpathogenic in experimental models. 118 
OPEN QUESTIONS AND FUTURE DIRECTIONS
We anticipate that further heterogeneity will be recognized in NMOSD. Currently recognized heterogeneity in NMOSD includes clinical cases mediated by AQP4-IgG and others by antibodies with myelin-directed rather than astrocyte-directed targets. Also, the variable nature of pathology apparently induced by AQP4-IgG interaction with its target can vary from activation of transcriptional pathways to modulation of AQP4 from the cell surface to complement-mediated cell lysis and downstream effects of complement cascade activation. We anticipate increasing reliance on antibody detection for diagnosis. It remains unclear whether antibody detection will eventually supplant reliance on clinical and radiologic findings for diagnosis. 119 However, at the present time, it is impossible to exclude NMOSD in seronegative patients. Future studies must validate the new diagnostic criteria, especially for seropositive patients, and long-term follow-up will be needed to determine that mimics of NMOSD are not being misdiagnosed.
Major improvements in the course of NMOSD have been achieved over the past decade by early recognition and differentiation from MS (and subsequent avoidance of treatments directed at preventing MS attacks, which are often ineffective and even potentially harmful). The effectiveness of current therapy, although not assessed by randomized trials, is generally good to excellent for most patients. However, immunosuppression is associated with infections and other risks and is incompletely effective. For occasional patients, it is not very effective at all. The prospects of antigen-specific therapeutics (eg, aquaporumab) and antigen-specific tolerization are tantalizing. However, they pose many challenges including delivery of therapeutics to AQP4 channels on the astrocyte foot process in a timely manner when treating attacks and in a durable fashion when striving to prevent attacks. An immediate challenge is the search for biomarkers to assess disease activity and the need for therapy and conversely determine when long-term immunosuppressive treatment is no longer necessary.
CONCLUSION
New diagnostic criteria have expanded the spectrum of NMOSD to include patients with recurrent myelitis only, recurrent optic neuritis only, and with certain brain syndromes. Neuromyelitis optica spectrum disorder remains a clinical diagnosis that requires a compatible clinical syndrome. In AQP4-IgGeseropositive patients, only a single clinical event is required. Neither optic neuritis nor myelitis, both requisite syndromes for a confident diagnosis until 2015, is now obligatory. Neuromyelitis optica spectrum disorder diagnosis is also possible in AQP4-IgGeseronegative cases, but such patients are likely heterogeneous. Emerging data suggest that another pathogenic antibody, MOG-IgG, defines a subset of patients with overlapping but different group demographic and clinical characteristics; the prognosis in this subgroup is poorly defined. Treatment for NMOSD has not yet been rigorously established on the basis of clinical trials, but considerable retrospective and uncontrolled prospective experience suggests that patients with NMOSD do not respond to many different MS treatments, and some of these treatments may even be harmful. Multiple studies, albeit uncontrolled, suggest that azathioprine, MMF, or rituximab are effective in reducing the frequency of attacks. 
